Groupama Asset Managment Acquires 30,562 Shares of Thermo Fisher Scientific Inc. $TMO

Groupama Asset Managment lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.5% during the fourth quarter, HoldingsChannel reports. The firm owned 275,578 shares of the medical research company’s stock after purchasing an additional 30,562 shares during the quarter. Thermo Fisher Scientific accounts for about 2.3% of Groupama Asset Managment’s investment portfolio, making the stock its 11th biggest holding. Groupama Asset Managment’s holdings in Thermo Fisher Scientific were worth $159,684,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TMO. High Note Wealth LLC raised its holdings in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares during the period. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $28,000. JPL Wealth Management LLC purchased a new stake in Thermo Fisher Scientific during the third quarter valued at about $28,000. Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $29,000. Finally, Olistico Wealth LLC bought a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $29,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $465.98 on Friday. The company has a market cap of $173.17 billion, a PE ratio of 25.62, a P/E/G ratio of 2.04 and a beta of 0.88. The business has a 50 day moving average of $477.34 and a 200 day moving average of $523.72. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $643.99. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period in the prior year, the business earned $5.15 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Royal Bank Of Canada set a $490.00 price target on Thermo Fisher Scientific and gave the company a “sector perform” rating in a research report on Thursday, May 14th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective for the company. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $608.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.